[Association of the polymorphisms in NURR1 gene with Parkinson's disease].
Wu Y, Peng R, Chen W, Zhang J, Li T, Wang Y, Gou Y, Yuan G
This study finds that a specific genetic variation in the NR4A2 gene is more common in people who develop Parkinson's disease before age 50. The research does not identify any link between this gene variant and other forms of Parkinson's or general population risk.
- The IVS6+18insG variant links to early-onset Parkinson's under age 50.
- No association exists for the c.-2922(C)2-3 promoter site.
- Study focuses on Han Chinese patients and controls.
- Findings do not apply to NR4A2 developmental syndromes.
NR4A2 controls the differentiation of selective dopaminergic nuclei in the zebrafish brain.
Blin M, Norton W, Bally-Cuif L, Vernier P
This study confirms that NR4A2 is essential for the development of dopamine-producing neurons in zebrafish and demonstrates that reduced NR4A2 function causes lifelong hyperactivity. These findings provide preclinical evidence that NR4A2 regulates both neuronal differentiation and locomotor behavior, supporting its role in the neurodevelopmental phenotypes seen in humans.
- NR4A2 drives dopamine neuron differentiation in zebrafish brain regions homologous to mammals.
- Reduced NR4A2 function causes persistent hyperactivity throughout the fish's life.
- NR4A2 controls progenitor commitment, not just final dopamine enzyme expression.
- Results align with mouse models showing behavioral impacts of NR4A2 haploinsufficiency.
Decreased NURR1 gene expression in patients with Parkinson's disease.
Le W, Pan T, Huang M, Xu P, Xie W, Zhu W, Zhang X, Deng H, Jankovic J
This study finds that NURR1 gene expression is significantly lower in the blood cells of adults with Parkinson's disease compared to healthy controls. The reduction correlates with increased disease risk in older women, older men, and Caucasians, suggesting systemic involvement of the dopaminergic system.
- NURR1 levels are significantly decreased in Parkinson's patients' blood cells.
- Lower expression links to higher PD risk in specific demographic groups.
- Medication status does not affect observed NURR1 expression levels.
- Findings suggest systemic biological changes beyond the brain in Parkinson's.
Nr4a2 is essential for the differentiation of dopaminergic neurons during zebrafish embryogenesis.
Luo GR, Chen Y, Li XP, Liu TX, Le WD
This study confirms that the Nr4a2 gene is required for dopaminergic neurons to differentiate and mature in zebrafish embryos. Reducing Nr4a2 levels decreases dopamine-producing neurons and dopamine levels, but these effects can be partially reversed by introducing mouse Nr4a2 mRNA.
- Nr4a2 drives the differentiation of dopaminergic neurons in zebrafish embryogenesis.
- Lowering Nr4a2 reduces both dopamine neuron count and dopamine transmitter levels.
- Mouse Nr4a2 mRNA partially rescues these deficits, suggesting functional conservation.
- The gene affects neuronal maturation rather than initial survival of progenitors.
Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo.
Pan T, Zhu W, Zhao H, Deng H, Xie W, Jankovic J, Le W
Reduced levels of the Nurr1 protein make dopaminergic neurons more vulnerable to damage caused by environmental toxins that disrupt cellular waste disposal. This increased susceptibility leads to greater neuron death and dopamine loss in animal models exposed to such stressors. The findings suggest that genetic variations lowering Nurr1 function could increase risk for neurodegeneration when combined with specific environmental exposures.
- Lower Nurr1 levels increase vulnerability of dopaminergic neurons to proteasome inhibitor toxicity.
- Nurr1 overexpression protects cells from injury caused by impaired cellular waste disposal systems.
- Mice with one copy of the Nurr1 gene show greater neuron loss and dopamine reduction under stress.
- The study links genetic susceptibility (low Nurr1) with environmental triggers for neuron damage.
The beta-chemokines CCL2 and CCL7 are two novel differentiation factors for midbrain dopaminergic precursors and neurons.
Edman LC, Mira H, Arenas E
The study identifies CCL2 and CCL7 as factors that promote the differentiation of midbrain dopaminergic neurons in cell cultures. These findings suggest a potential mechanism for enhancing dopamine neuron development, which is relevant to understanding NR4A2/Nurr1 function.
- CCL2 and CCL7 enhance differentiation of Nurr1-positive precursors into dopamine neurons.
- Nurr1 regulates CCL7 expression, linking it to dopamine neuron development.
- The study uses primary precursor cultures, not human patients or animal models.
- Results suggest potential utility for cell replacement therapies in Parkinson's disease.
Heroin abuse is characterized by discrete mesolimbic dopamine and opioid abnormalities and exaggerated nuclear receptor-related 1 transcriptional decline with age.
Horvath MC, Kovacs GG, Kovari V, Majtenyi K, Hurd YL, Keller E
This study finds that long-term heroin use in humans causes specific declines in dopamine regulation and the NR4A2 protein (Nurr1) within brain reward circuits, with these deficits worsening significantly as users age. The research highlights a direct link between opiate abuse and the degradation of the very neural pathways often impaired in NR4A2-related syndromes.
- Heroin use reduces dopamine transporter mRNA specifically in mesolimbic brain regions.
- NR4A2 (Nurr1) expression declines sharply with age in heroin users compared to controls.
- Opioid receptor signaling dysregulation is selective to the ventral tegmental area.
- The study provides human evidence linking drug abuse to NR4A2 pathway dysfunction.
Treatment of Parkinson disease with C17.2 neural stem cells overexpressing NURR1 with a recombined republic-deficit adenovirus containing the NURR1 gene.
Li QJ, Tang YM, Liu J, Zhou DY, Li XP, Xiao SH, Jian DX, Xing YG
This study shows that modifying neural stem cells to overexpress the NURR1 gene improves behavioral and histological outcomes in rats with Parkinson's disease. The treatment enhances the differentiation of stem cells into neurons, suggesting a potential therapeutic strategy for dopaminergic loss.
- Researchers used adenovirus to boost NURR1 expression in neural stem cells.
- Transplanted cells differentiated more effectively into neurons with NURR1 overexpression.
- Treated rats showed better behavioral and histological outcomes than controls.
- The approach demonstrates potential for replacing lost dopaminergic neurons.
Association analysis of 15 polymorphisms within 10 candidate genes for antisocial behavioural traits.
Prichard ZM, Jorm AF, Mackinnon A, Easteal S
This study finds that specific genetic variations in the NR4A2 gene are associated with antisocial behavioral traits in women. The research focuses on personality and lifestyle indicators rather than the neurodevelopmental or motor symptoms characteristic of NR4A2 syndrome.
- NR4A2 variants associate with antisocial traits specifically in female participants.
- The study examines behavioral phenotypes, not clinical NR4A2 syndrome features.
- TFAP2B showed stronger statistical significance than NR4A2 after corrections.
- Findings relate to general population behavioral variation, not disease mechanisms.
9-Methyl-beta-carboline up-regulates the appearance of differentiated dopaminergic neurones in primary mesencephalic culture.
Hamann J, Wernicke C, Lehmann J, Reichmann H, Rommelspacher H, Gille G
A specific beta-carboline compound promotes the growth and survival of dopaminergic neurons in laboratory cell cultures while reducing cellular stress and inflammation. This chemical also stimulates key genetic pathways, including Nurr1, that are essential for dopamine neuron development.
- 9-methyl-beta-carboline increases differentiated dopaminergic neurons in mesencephalic cultures.
- The compound reduces cell death markers and inflammatory gene expression.
- It upregulates Nurr1 and other transcription factors critical for dopamine neuron identity.
- Dopamine uptake capacity improves, though total dopamine levels show only slight changes.
A Nurr1 point mutant, implicated in Parkinson's disease, uncouples ERK1/2-dependent regulation of tyrosine hydroxylase transcription.
Jacobsen KX, MacDonald H, Lemonde S, Daigle M, Grimes DA, Bulman DE, Albert PR
This study identifies a specific NURR1 mutation found in a Parkinson's disease patient that disrupts the protein's ability to regulate dopamine synthesis genes. The mutation prevents normal signaling pathways from activating the gene responsible for producing tyrosine hydroxylase, the enzyme needed to make dopamine. This provides a molecular explanation for how this genetic change can lead to reduced dopamine levels.
- A Parkinson's patient carries an NR4A2 mutation near a key phosphorylation site.
- The mutation blocks NURR1 from activating the tyrosine hydroxylase gene promoter.
- Normal dopamine signaling fails to rescue transcriptional activity in mutant cells.
- This mechanism links the variant to impaired dopamine synthesis and Parkinson's risk.
Foxa1 and Foxa2 regulate multiple phases of midbrain dopaminergic neuron development in a dosage-dependent manner.
Ferri AL, Lin W, Mavromatakis YE, Wang JC, Sasaki H, Whitsett JA, Ang SL
The transcription factors Foxa1 and Foxa2 control the development of midbrain dopaminergic neurons by regulating key genes like Nurr1 (NR4A2) in a dosage-dependent manner. This study identifies specific molecular mechanisms where these upstream regulators influence NR4A2 expression during different stages of neuron maturation.
- Foxa1 and Foxa2 regulate neurogenesis in midbrain dopaminergic progenitors via Ngn2.
- These factors control Nurr1 (NR4A2) expression in immature neurons.
- They also regulate mature neuron markers like tyrosine hydroxylase.
- Different gene dosages of Foxa1 and Foxa2 drive distinct developmental phases.
Transplantation of post-mitotic human neuroteratocarcinoma-overexpressing Nurr1 cells provides therapeutic benefits in experimental stroke: in vitro evidence of expedited neuronal differentiation and GDNF secretion.
Hara K, Matsukawa N, Yasuhara T, Xu L, Yu G, Maki M, Kawase T, Hess DC, Kim SU, Borlongan CV
Transplanting human cells engineered to overexpress Nurr1 reduces brain damage and improves movement in rats after a stroke. The modified cells differentiate into neurons faster and secrete GDNF, a protein that supports nerve survival.
- Nurr1-overexpressing cells survive and become neurons in rat brains after stroke.
- Treated rats show less brain cell loss and better motor function than controls.
- The cells secrete GDNF, which likely helps protect surviving brain tissue.
- This is a preclinical animal study using stroke models, not human trials.
Enhancement of dopaminergic properties and protection mediated by neuronal activation of Ras in mouse ventral mesencephalic neurones.
Chakrabarty K, Serchov T, Mann SA, Dietzel ID, Heumann R
Activating the Ras signaling pathway in mouse dopaminergic neurons enhances their survival and differentiation while protecting them from chemical damage. This mechanism increases Nurr1 expression, which is directly relevant to NR4A2 function, suggesting that similar intracellular therapies might one day support dopamine neuron health.
- Ras activation boosts Nurr1 levels and dopaminergic neuron numbers in mouse models.
- Treated neurons resist degeneration caused by toxic stimuli like 6-hydroxydopamine.
- The study uses transgenic mice, not human clinical data.
- Basic electrical properties of the neurons remain unchanged despite enhanced survival.
Regulation of GTP cyclohydrolase I expression by orphan receptor Nurr1 in cell culture and in vivo.
Gil M, McKinney C, Lee MK, Eells JB, Phyillaier MA, Nikodem VM
The transcription factor Nurr1 directly regulates the expression of GTP cyclohydrolase I, the enzyme responsible for producing BH4, an essential cofactor for dopamine synthesis. This study confirms a molecular link between Nurr1 and the biochemical machinery required to create dopamine in developing neurons.
- Nurr1 activates GTPCH transcription indirectly via the proximal promoter region.
- GTPCH levels drop significantly in mice lacking functional Nurr1.
- BH4 is a critical cofactor for tyrosine hydroxylase in dopamine synthesis.
- This mechanism was observed in mouse models and cell culture experiments.
Dopaminergic neurons intrinsic to the striatum.
Huot P, Parent A
The brain contains a small population of dopamine-producing neurons within the striatum that increase in number when dopamine levels are low, such as in Parkinson's disease. This natural compensatory mechanism is suppressed by L-dopa treatment, suggesting that enhancing these local neurons could potentially help manage symptoms.
- Striatal neurons produce dopamine and express Nurr1, the protein affected by NR4A2 mutations.
- These neurons increase in number when brain dopamine levels drop significantly.
- L-dopa treatment stops this natural increase in neuron numbers.
- Boosting these local neurons might offer a new way to treat Parkinson's symptoms.
Generation of functional dopamine neurons from neural precursor cells isolated from the subventricular zone and white matter of the adult rat brain using Nurr1 overexpression.
Shim JW, Park CH, Bae YC, Bae JY, Chung S, Chang MY, Koh HC, Lee HS, Hwang SJ, Lee KH, Lee YS, Choi CY, Lee SH
Overexpressing the Nurr1 protein in adult rat brain cells forces them to become functional dopamine neurons that restore movement in Parkinsonian rats. This study proves that adult neural precursor cells can be converted into dopamine-producing cells using genetic modification, offering a potential cell-replacement strategy for neurodegenerative diseases.
- Nurr1 overexpression converts adult rat brain precursor cells into functional dopamine neurons.
- Engineered neurons release dopamine and integrate into the host brain in vivo.
- Transplanted cells reverse behavioral deficits in a rat model of Parkinson's disease.
- Adult neural precursors offer an alternative to fetal tissue for cell replacement therapy.
Ngn2 and Nurr1 act in synergy to induce midbrain dopaminergic neurons from expanded neural stem and progenitor cells.
Andersson EK, Irvin DK, Ahlsiö J, Parmar M
Combining Ngn2 and Nurr1 genes successfully generates mature midbrain dopaminergic neurons from expanded mouse progenitor cells, whereas using either gene alone produces only immature or non-dopaminergic cells. This study demonstrates a specific molecular synergy required for proper neuronal development in a preclinical mouse model.
- Ngn2 and Nurr1 work together to create mature dopaminergic neurons from mouse progenitors.
- Using Nurr1 alone creates immature cells that lack key dopaminergic markers.
- Using Ngn2 alone increases general neuronal differentiation but not dopaminergic identity.
- The study uses fetal mouse brain cells, not human tissue or patients.
Acquisition of in vitro and in vivo functionality of Nurr1-induced dopamine neurons.
Park CH, Kang JS, Shin YH, Chang MY, Chung S, Koh HC, Zhu MH, Oh SB, Lee YS, Panagiotakos G, Tabar V, Studer L, Lee SH
Engineered rat neural precursor cells expressing Nurr1 alongside specific genetic factors mature into functional dopamine neurons that survive transplantation and reverse motor deficits in Parkinsonian rats. This study demonstrates a viable protocol for generating transplantable dopamine neurons, offering a potential future cell-based therapy strategy.
- Nurr1 alone produces immature dopamine neurons with limited function in animal models.
- Adding Bcl-XL and Sonic hedgehog or Mash1 drives full neuronal maturation in vitro.
- Transplanted engineered cells survive and integrate into the rat brain striatum.
- The matured neurons reverse behavioral deficits associated with Parkinson's disease in rats.
Identification of a series of highly potent activators of the Nurr1 signaling pathway.
Hintermann S, Chiesi M, von Krosigk U, Mathé D, Felber R, Hengerer B
Researchers identify a small molecule that strongly activates the Nurr1 signaling pathway and can cross into the brain. This compound serves as a chemical tool to study how NR4A2 functions rather than a proven treatment for patients.
- The drug candidate is highly potent at activating Nurr1 signaling in laboratory settings.
- It successfully penetrates the blood-brain barrier, a necessary step for potential therapies.
- This work focuses on chemical development and does not test efficacy in humans or animals.
Control of neurogenesis and tyrosine hydroxylase expression in neural progenitor cells through bHLH proteins and Nurr1.
Kim HJ, Sugimori M, Nakafuku M, Svendsen CN
Overexpressing Nurr1 alongside specific neural transcription factors drives the creation of dopamine-producing neurons from progenitor cells in a laboratory setting. This study provides proof-of-concept that multiple genetic factors can direct cell fate toward the dopaminergic lineage, though fully functional neurons require additional signals.
- Nurr1 increases tyrosine hydroxylase levels in both neurons and glial cells.
- Combining Nurr1 with Ngn2 or Mash1 generates small numbers of dopamine-positive neurons.
- Neurons from ventral midbrain progenitors are larger than those from striatal progenitors.
- The study demonstrates proof-of-concept for driving dopaminergic fate in vitro.
- Additional factors remain necessary to produce fully functional dopamine neurons.
Transplanted dopamine neurons derived from primate ES cells preferentially innervate DARPP-32 striatal progenitors within the graft.
Ferrari D, Sanchez-Pernaute R, Lee H, Studer L, Isacson O
Dopamine neurons derived from primate embryonic stem cells successfully integrate into the brain and restore movement in Parkinson's disease rat models. The study confirms these lab-grown neurons form correct connections with target brain regions and express key developmental markers like Nurr1.
- Primate stem cell-derived dopamine neurons improve movement in Parkinsonian rats.
- Neurons express Nurr1, a transcription factor also known as NR4A2.
- Grafted neurons form specific connections with striatal target cells.
- Longer differentiation periods produce more mature, homogeneous neuron populations.
Identification of a potent agonist of the orphan nuclear receptor Nurr1.
Dubois C, Hengerer B, Mattes H
Researchers identified a chemical compound that strongly activates Nurr1, the protein produced by the NR4A2 gene. This finding provides a potential starting point for developing drugs that could boost Nurr1 activity in the future.
- The study discovered a potent agonist that activates the Nurr1 receptor.
- This is preclinical chemistry work performed in laboratory settings.
- No human trials or clinical data are included in this report.
- The compound serves as a tool for further drug development research.
Translated mutation in the Nurr1 gene as a cause for Parkinson's disease.
Grimes DA, Han F, Panisset M, Racacho L, Xiao F, Zou R, Westaff K, Bulman DE
This study screens the NR4A2 gene in a large group of Parkinson's disease patients and finds that coding mutations are rare. It identifies one novel mutation in a single patient, but this finding does not establish a clear link between NR4A2 variants and the specific neurodevelopmental syndrome seen in your child.
- Researchers screened 202 Parkinson's patients for NR4A2 mutations.
- Coding mutations in NR4A2 are rare in this Parkinson's cohort.
- One novel mutation was found in one non-familial patient.
- The study does not address the neurodevelopmental phenotype of NR4A2 syndrome.
Transforming growth factor beta is required for differentiation of mouse mesencephalic progenitors into dopaminergic neurons in vitro and in vivo: ectopic induction in dorsal mesencephalon.
Roussa E, Wiehle M, Dünker N, Becker-Katins S, Oehlke O, Krieglstein K
Transforming growth factor beta (TGF-beta) is essential for the development of dopamine-producing neurons in the midbrain, as shown by reduced neuron counts in mice lacking this signal. The study demonstrates that TGF-beta works with other factors to guide progenitor cells toward becoming dopaminergic neurons.
- TGF-beta2 and TGF-beta3 are required for midbrain progenitors to become dopamine neurons.
- Mice missing these signals show significantly fewer dopamine neurons in the ventral midbrain.
- Adding TGF-beta increases dopamine neuron markers in cultured mouse brain cells.
- The effect involves specific cellular pathways like Smad and p38 MAPK.
Reduced tyrosine hydroxylase and GTP cyclohydrolase mRNA expression, tyrosine hydroxylase activity, and associated neurochemical alterations in Nurr1-null heterozygous mice.
Eells JB, Misler JA, Nikodem VM
Reduced Nurr1 levels in mice lower the expression of key enzymes needed for dopamine production, leading to decreased dopamine synthesis and altered dopamine levels in specific brain regions. This mechanism explains how partial loss of NR4A2 function can disrupt dopamine pathways relevant to the child's condition.
- Nurr1 haploinsufficiency reduces mRNA for tyrosine hydroxylase and GTP cyclohydrolase.
- In vivo tyrosine hydroxylase activity drops significantly in mouse striatum and nucleus accumbens.
- Dopamine synthesis impairment varies between mesolimbic and nigrostriatal neuron populations.
- Basal dopamine levels remain stable but are vulnerable to synthesis inhibition or stress.
The dopamine D2 receptor regulates the development of dopaminergic neurons via extracellular signal-regulated kinase and Nurr1 activation.
Kim SY, Choi KC, Chang MS, Kim MH, Kim SY, Na YS, Lee JE, Jin BK, Lee BH, Baik JH
Dopamine signaling through the D2 receptor promotes the development of dopaminergic neurons by activating Nurr1 via the ERK pathway. This mechanism explains why reduced D2 receptor function leads to fewer dopaminergic neurons during embryonic development.
- D2 receptor activation increases dopaminergic neuron numbers and neurite growth.
- This effect requires ERK signaling to activate Nurr1 transcriptional activity.
- Mice lacking D2 receptors show significantly reduced midbrain dopaminergic neurons.
- Nurr1 expression is selectively reduced in the absence of D2 receptor signaling.
Neural precursors derived from embryonic stem cells, but not those from fetal ventral mesencephalon, maintain the potential to differentiate into dopaminergic neurons after expansion in vitro.
Chung S, Shin BS, Hwang M, Lardaro T, Kang UJ, Isacson O, Kim KS
This study shows that neural precursors derived from embryonic stem cells maintain the ability to become dopamine-producing neurons after being grown in a lab, whereas those taken directly from fetal brain tissue lose this potential. The expanded stem cell-derived neurons successfully produced dopamine and expressed key markers like Nurr1 when transplanted into mice.
- Embryonic stem cell-derived neural precursors retain the ability to become dopamine neurons after lab expansion.
- Fetal ventral mesencephalon precursors lose their potential to differentiate into dopamine neurons during expansion.
- Expanded stem cell neurons express Nurr1, Pitx3, and release significant amounts of dopamine.
- Transplanted expanded neurons generate mature dopamine neurons in mouse brains with low tumor risk.
Cooperative transcription activation by Nurr1 and Pitx3 induces embryonic stem cell maturation to the midbrain dopamine neuron phenotype.
Martinat C, Bacci JJ, Leete T, Kim J, Vanti WB, Newman AH, Cha JH, Gether U, Wang H, Abeliovich A
Nurr1 and Pitx3 work together to mature stem cells into midbrain dopamine neurons in laboratory cultures. This finding identifies a specific molecular partnership required for the development of these critical brain cells.
- Nurr1 and Pitx3 cooperate to drive stem cell maturation into dopamine neurons.
- Neither factor alone is sufficient to induce the mature neuron phenotype.
- This mechanism was observed in both mouse and human embryonic stem cells.
- The study focuses on basic developmental biology rather than clinical treatment.
Neurogenin 2 is required for the development of ventral midbrain dopaminergic neurons.
Kele J, Simplicio N, Ferri AL, Mira H, Guillemot F, Arenas E, Ang SL
Neurogenin 2 drives the formation of midbrain dopaminergic neurons, which are the same cell type affected in NR4A2-related syndromes. This study shows that Neurogenin 2 is essential for these neurons to develop from stem cells into mature, functional nerve cells.
- Neurogenin 2 is required for midbrain dopaminergic neuron development.
- It helps progenitor cells become Nurr1-positive precursors.
- Nurr1 is the protein encoded by the NR4A2 gene.
- Mash1 can partially compensate if Neurogenin 2 is missing.
- This confirms a specific genetic pathway for these neurons.
Absence of previously reported variants in the SCNA (G88C and G209A), NR4A2 (T291D and T245G) and the DJ-1 (T497C) genes in familial Parkinson's disease from the GenePD study.
Karamohamed S, Golbe LI, Mark MH, Lazzarini AM, Suchowersky O, Labelle N, Guttman M, Currie LJ, Wooten GF, Stacy M, Saint-Hilaire M, Feldman RG, Liu J, Shoemaker CM, Wilk JB, DeStefano AL, Latourelle JC, Xu G, Watts R, Growdon J, Lew M, Waters C, Vieregge P, Pramstaller PP, Klein C, Racette BA, Perlmutter JS, Parsian A, Singer C, Montgomery E, Baker K, Gusella JF, Herbert A, Myers RH
This study screened for specific NR4A2 variants in families with Parkinson's disease and found none of the previously reported mutations. The results indicate that these particular variants do not contribute to familial Parkinson's disease in this cohort.
- Researchers tested 292 familial Parkinson's disease cases from the GenePD study.
- Six specific genetic variations in SCNA, NR4A2, and DJ-1 were analyzed.
- None of the targeted NR4A2 variants were found in any participant.
- Other genes or variants likely account for the familial risk in these families.
Nitric oxide mediates increased susceptibility to dopaminergic damage in Nurr1 heterozygous mice.
Imam SZ, Jankovic J, Ali SF, Skinner JT, Xie W, Conneely OM, Le WD
Mice with one copy of the Nurr1 gene show higher levels of nitric oxide, which triggers cell death pathways in dopamine neurons. This mechanism explains why these mice are more sensitive to damage from dopaminergic toxins like methamphetamine.
- Nurr1 heterozygous mice have elevated neuronal nitric oxide synthase in the striatum.
- Increased nitric oxide activates apoptotic cascades via cytochrome C and caspase-3.
- Methamphetamine exposure worsens these cellular damage markers in Nurr1 +/- mice.
- The study identifies a specific molecular pathway for dopamine neuron vulnerability.
In search of genes involved in neurodegenerative disorders.
Pardo LM, van Duijn CM
This review identifies NR4A2 as one of the seven genes linked to Parkinson's disease, noting that these genetic findings mostly explain early-onset cases rather than the common forms of the disorder. The paper summarizes current knowledge on Alzheimer's and Parkinson's genetics but does not provide new clinical data or treatment insights for NR4A2-related syndromes.
- NR4A2 is one of seven genes associated with Parkinson's disease.
- These identified genes primarily explain early-onset cases of the disorder.
- The paper reviews genetics of Alzheimer's and Parkinson's broadly.
- It discusses hypotheses about common versus rare genetic variants.
- No specific clinical data or treatment options for NR4A2 are presented.
Biological effects of pramipexole on dopaminergic neuron-associated genes: relevance to neuroprotection.
Pan T, Xie W, Jankovic J, Le W
Pramipexole increases levels of Nurr1 and other dopamine-related proteins in human nerve cells, suggesting it may protect these neurons. This effect appears to work through the D3 dopamine receptor.
- Pramipexole raises Nurr1 mRNA and protein levels in human neuroblastoma cells.
- The drug also increases DAT and VMAT2 gene expression.
- Blocking the D3 receptor stops the increase in Nurr1.
- Blocking the D2 receptor does not affect Nurr1 levels.
- Results suggest a mechanism for pramipexole's neuroprotective effects.
Identification and characterization of human NR4A2 polymorphisms in attention deficit hyperactivity disorder.
Smith KM, Bauer L, Fischer M, Barkley R, Navia BA
This study identifies two common genetic variations in the NR4A2 gene and tests whether they are linked to ADHD. It finds no significant association between these specific polymorphisms and ADHD in the tested human cohorts.
- Researchers identified a CA repeat and a DeltaC polymorphism in the NR4A2 gene.
- The study tested these variants for association with ADHD in humans.
- No significant link was found between these specific NR4A2 variations and ADHD.
- In vitro tests showed minor differences in promoter activity for one variant.
Age-dependent dopaminergic dysfunction in Nurr1 knockout mice.
Jiang C, Wan X, He Y, Pan T, Jankovic J, Le W
Older mice with one non-functional copy of the Nurr1 gene develop motor impairments and lose dopamine-producing neurons, mirroring aspects of Parkinson's disease. This suggests that reduced Nurr1 function may contribute to age-related decline in dopaminergic systems.
- Mice with one defective Nurr1 copy show motor deficits only when old.
- Old mutant mice lose dopamine-producing neurons in the brain.
- Striatum dopamine levels drop significantly in aged mutant mice.
- The study uses an animal model, not human patients.
- Findings relate to Parkinson's disease mechanisms, not NR4A2 syndrome directly.
Differentiation of the dopaminergic phenotype in the olfactory system of neonatal and adult mice.
Saino-Saito S, Sasaki H, Volpe BT, Kobayashi K, Berlin R, Baker H
This study maps how dopamine-producing neurons develop in the mouse olfactory system, identifying Nurr1 (NR4A2) as a key regulator of this process. It confirms that NR4A2 activity is essential for the differentiation and maintenance of these specific neurons during both neonatal and adult stages.
- Nurr1 regulates dopamine neuron development in mouse olfactory bulbs.
- Dopamine expression begins in migrating progenitor cells in neonates.
- Odor deprivation reduces Nurr1 expression, linking activity to regulation.
- Other genes like Dlx-1 and -2 do not regulate this pathway.
Fibroblast growth factor-20 promotes the differentiation of Nurr1-overexpressing neural stem cells into tyrosine hydroxylase-positive neurons.
Grothe C, Timmer M, Scholz T, Winkler C, Nikkhah G, Claus P, Itoh N, Arenas E
This study shows that FGF-20 helps stem cells with high Nurr1 levels mature into dopamine-producing neurons in rats. The research demonstrates that these engineered cells survive and function after transplantation, particularly in young animals.
- FGF-20 drives the differentiation of Nurr1-overexpressing stem cells into dopamine neurons.
- Transplanted cells survived and expressed tyrosine hydroxylase in rat brains.
- Neurite growth occurred only after grafts into postnatal, not adult, rats.
- The study uses animal models to explore cell therapy mechanisms for Parkinson's.
Genetic contributions to Parkinson's disease.
Huang Y, Cheung L, Rowe D, Halliday G
This review identifies NR4A2 (Nurr1) as a causative gene for familial Parkinson's disease, linking its mutations to the loss of dopamine neurons. It highlights that genetic variations in NR4A2 and other genes influence susceptibility to neurodegeneration through complex interactions with environmental factors.
- NR4A2 mutations cause pathology identical to alpha-synuclein mutations in Parkinson's disease.
- The paper reviews multiple genes affecting dopamine neuron survival and function.
- Genetic background significantly influences susceptibility to Parkinson's disease alongside environmental factors.
Pleiotrophin mRNA is highly expressed in neural stem (progenitor) cells of mouse ventral mesencephalon and the product promotes production of dopaminergic neurons from embryonic stem cell-derived nestin-positive cells.
Jung CG, Hida H, Nakahira K, Ikenaka K, Kim HJ, Nishino H
Pleiotrophin promotes the production of dopamine-producing neurons from stem cells and increases dopamine levels in laboratory cultures. This mechanism suggests that targeting pleiotrophin pathways could theoretically support dopaminergic neuron development, which is relevant to NR4A2-related movement disorders.
- Pleiotrophin boosts dopamine neuron production from stem cells in lab studies.
- The protein increases dopamine levels in cultured neural cells.
- Nurr1 expression rises when pleiotrophin is present.
- This effect matches known dopaminergic growth factors like sonic hedgehog.
- Findings are preclinical and do not involve human patients or treatments.